81 related articles for article (PubMed ID: 25269647)
1. Zerumbone suppresses EGF-induced CD44 expression through the inhibition of STAT3 in breast cancer cells.
Kim S; Kil WH; Lee J; Oh SJ; Han J; Jeon M; Jung T; Lee SK; Bae SY; Lee HC; Lee JH; Yi HW; Kim SW; Nam SJ; Lee JE
Oncol Rep; 2014 Dec; 32(6):2666-72. PubMed ID: 25269647
[TBL] [Abstract][Full Text] [Related]
2. Silibinin suppresses EGFR ligand-induced CD44 expression through inhibition of EGFR activity in breast cancer cells.
Kim S; Han J; Kim JS; Kim JH; Choe JH; Yang JH; Nam SJ; Lee JE
Anticancer Res; 2011 Nov; 31(11):3767-73. PubMed ID: 22110198
[TBL] [Abstract][Full Text] [Related]
3. Zerumbone suppresses the motility and tumorigenecity of triple negative breast cancer cells via the inhibition of TGF-β1 signaling pathway.
Kim S; Lee J; Jeon M; Lee JE; Nam SJ
Oncotarget; 2016 Jan; 7(2):1544-58. PubMed ID: 26637807
[TBL] [Abstract][Full Text] [Related]
4. Notch2 activation is protective against anticancer effects of zerumbone in human breast cancer cells.
Sehrawat A; Sakao K; Singh SV
Breast Cancer Res Treat; 2014 Aug; 146(3):543-55. PubMed ID: 25038880
[TBL] [Abstract][Full Text] [Related]
5. Osteopontin-induced migration of human mammary epithelial cells involves activation of EGF receptor and multiple signal transduction pathways.
Tuck AB; Hota C; Wilson SM; Chambers AF
Oncogene; 2003 Feb; 22(8):1198-205. PubMed ID: 12606946
[TBL] [Abstract][Full Text] [Related]
6. Elevated IL-1β expression induces invasiveness of triple negative breast cancer cells and is suppressed by zerumbone.
Jeon M; Han J; Nam SJ; Lee JE; Kim S
Chem Biol Interact; 2016 Oct; 258():126-33. PubMed ID: 27567548
[TBL] [Abstract][Full Text] [Related]
7. Ascofuranone suppresses EGF-induced HIF-1α protein synthesis by inhibition of the Akt/mTOR/p70S6K pathway in MDA-MB-231 breast cancer cells.
Jeong YJ; Cho HJ; Magae J; Lee IK; Park KG; Chang YC
Toxicol Appl Pharmacol; 2013 Dec; 273(3):542-50. PubMed ID: 24096035
[TBL] [Abstract][Full Text] [Related]
8. CD44 correlates with clinicopathological characteristics and is upregulated by EGFR in breast cancer.
Xu H; Wu K; Tian Y; Liu Q; Han N; Yuan X; Zhang L; Wu GS; Wu K
Int J Oncol; 2016 Oct; 49(4):1343-50. PubMed ID: 27499099
[TBL] [Abstract][Full Text] [Related]
9. Prolactin modulates phosphorylation, signaling and trafficking of epidermal growth factor receptor in human T47D breast cancer cells.
Huang Y; Li X; Jiang J; Frank SJ
Oncogene; 2006 Dec; 25(58):7565-76. PubMed ID: 16785991
[TBL] [Abstract][Full Text] [Related]
10. Epidermal growth factor: receptor and ligand expression in human breast cancer.
Murphy LC; Dotzlaw H; Wong MS; Miller T; Mrockowski B; Gong Y; Murphy LJ
Semin Cancer Biol; 1990 Oct; 1(5):305-15. PubMed ID: 2103505
[TBL] [Abstract][Full Text] [Related]
11. An unexpected biochemical and functional interaction between gp130 and the EGF receptor family in breast cancer cells.
Grant SL; Hammacher A; Douglas AM; Goss GA; Mansfield RK; Heath JK; Begley CG
Oncogene; 2002 Jan; 21(3):460-74. PubMed ID: 11821958
[TBL] [Abstract][Full Text] [Related]
12. Induction of fibronectin in response to epidermal growth factor is suppressed by silibinin through the inhibition of STAT3 in triple negative breast cancer cells.
Kim S; Jeon M; Lee J; Han J; Oh SJ; Jung T; Nam SJ; Kil WH; Lee JE
Oncol Rep; 2014 Nov; 32(5):2230-6. PubMed ID: 25175149
[TBL] [Abstract][Full Text] [Related]
13. An update of the mechanisms of resistance to EGFR-tyrosine kinase inhibitors in breast cancer: Gefitinib (Iressa) -induced changes in the expression and nucleo-cytoplasmic trafficking of HER-ligands (Review).
Ferrer-Soler L; Vazquez-Martin A; Brunet J; Menendez JA; De Llorens R; Colomer R
Int J Mol Med; 2007 Jul; 20(1):3-10. PubMed ID: 17549382
[TBL] [Abstract][Full Text] [Related]
14. MUC20 overexpression predicts poor prognosis and enhances EGF-induced malignant phenotypes via activation of the EGFR-STAT3 pathway in endometrial cancer.
Chen CH; Wang SW; Chen CW; Huang MR; Hung JS; Huang HC; Lin HH; Chen RJ; Shyu MK; Huang MC
Gynecol Oncol; 2013 Mar; 128(3):560-7. PubMed ID: 23262208
[TBL] [Abstract][Full Text] [Related]
15. Role of epidermal growth factor receptor and STAT-3 activation in autonomous proliferation of SUM-102PT human breast cancer cells.
Sartor CI; Dziubinski ML; Yu CL; Jove R; Ethier SP
Cancer Res; 1997 Mar; 57(5):978-87. PubMed ID: 9041204
[TBL] [Abstract][Full Text] [Related]
16. Theanaphthoquinone inhibits fatty acid synthase expression in EGF-stimulated human breast cancer cells via the regulation of EGFR/ErbB-2 signaling.
Weng MS; Ho CT; Ho YS; Lin JK
Toxicol Appl Pharmacol; 2007 Jan; 218(2):107-18. PubMed ID: 17182072
[TBL] [Abstract][Full Text] [Related]
17. Complex post-transcriptional regulation of EGF-receptor expression by EGF and TGF-alpha in human prostate cancer cells.
Seth D; Shaw K; Jazayeri J; Leedman PJ
Br J Cancer; 1999 May; 80(5-6):657-69. PubMed ID: 10360641
[TBL] [Abstract][Full Text] [Related]
18. Involvement of transforming growth factor alpha/epidermal growth factor receptor autocrine growth mechanism in an ovarian cancer cell line in vitro.
Morishige K; Kurachi H; Amemiya K; Adachi H; Inoue M; Miyake A; Tanizawa O; Sakoyama Y
Cancer Res; 1991 Nov; 51(21):5951-5. PubMed ID: 1718591
[TBL] [Abstract][Full Text] [Related]
19. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
[TBL] [Abstract][Full Text] [Related]
20. Grb2 regulates Stat3 activation negatively in epidermal growth factor signalling.
Zhang T; Ma J; Cao X
Biochem J; 2003 Dec; 376(Pt 2):457-64. PubMed ID: 14498832
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
